News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Trastuzumab deruxtecan therapy in patients with HER2-positive metastatic breast cancer
Aug 6, 2024, 02:02

Trastuzumab deruxtecan therapy in patients with HER2-positive metastatic breast cancer

Chief of Division of Hematology and Medical Oncology at shared a post on LinkedIn about a paper titled “Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial” published in The Lancet Oncology.

Authors: Tanja Fehm, Francesco Cottone, Kyle Dunton, Fabrice André, Ian Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruiz Borrego, Rinat Yerushalmi, Francois P Duhoux, Toshimi Takano, Wenjing Lu, Anton Egorov, Sung-Bae Kim.

Trastuzumab deruxtecan therapy in patients with HER2-positive metastatic breast cancer

“Trastuzumab deruxtecan therapy improved patient reported outcomes in patients with HER2-positive metastatic breast cancer who progressed after receiving trastuzumab-DM1. A recent update from the DESTINY Breast02 trial confirms trastuzumab deruxtecan as the best option for this population.

Fehm T, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer, DESTINY-Breast02: patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology 2024.”

Trastuzumab deruxtecan therapy in patients with HER2-positive metastatic breast cancer

Source:

Anne Armstrong Anton Egorov cancer Deruxtecan DESTINY-Breast02 Fabrice Andre Francesco Cottone Francisco Esteva Francois P Duhoux HER2-positive Ian Krop Kyle Dunton Lenox Hill Hospital Manuel Ruiz Borrego metastatic breast cancer Michelino De Laurentiis OncoDaily Oncology Phase 3 Trial Rinat Yerushalmi Sung-Bae Kim Tanja Fehm The Lancet Oncology Toshimi Takano trastuzumab Wenjing Lu Yasuo Miyoshi Yeon Hee Park
Special Coverage
Insight
Nov 20, 2024, 20:44
Baris Turkbey: Excited to announce NCI Molecular Imaging members presenting their research at RSNA2024
Blog
Nov 20, 2024, 20:38
Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
Insight
Nov 20, 2024, 19:12
Nareg Varjabedian: Antidiabetic Drugs and Cancer Prevention
Insight
Nov 20, 2024, 19:12
Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer
Insight
Nov 20, 2024, 19:12
Physicians’ perspectives on cancer-related fatigue management: A cross-sectional survey study in Germany - MASCC
Insight
Nov 20, 2024, 19:12
Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.
Blog
Nov 20, 2024, 19:12
Rahul Gosain: Role of diet and exercise in cancer with Neil Iyengar